Echoing this, BioNTech stock's Schaeffer's put/call open interest ratio (SOIR) of 1.14 sits higher than 98% of annual ...

BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...

In a report released today, Harry Gillis from Berenberg Bank upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price target of $130.00. The company’s shares closed yesterday at $101.87.

BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to strengthen its oncology pipeline. With the acquisition, BNTX will gain full ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated ...

Shares of BioNTech stock opened at $99.72 on Thursday. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ...

The Nasdaq 100 recovered from early losses and turned higher on strength in Super Micro Computer and Nvidia. Stock indexes also found support in strong earnings results from Walmart, which rose more ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX ...